Journal
JCI INSIGHT
Volume 6, Issue 7, Pages -Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.127933
Keywords
-
Categories
Funding
- National Health and Medical Research Council [1011153, 1060074]
- Hunter Medical Research Institute
- Asthma UK Clinical Chair [CH11SJ]
- National Institute of Health Research (NIHR) Emeritus Senior Investigator
- European Research Council [788575]
- NIHR Imperial Biomedical Research Centre
- European Research Council (ERC) [788575] Funding Source: European Research Council (ERC)
- National Health and Medical Research Council of Australia [1060074] Funding Source: NHMRC
Ask authors/readers for more resources
Virus-induced respiratory infections, particularly with rhinoviruses, have significant health impacts on children. Inhibition of miRNA 122 (miR-122) shows promise in reducing inflammation and airway hyperreactivity induced by RV infections, with potential implications for treating bronchiolitis and asthma exacerbations. High miR-122 levels are associated with poorer clinical outcomes, suggesting anti-miR-122 oligonucleotides could be a therapeutic option.
Virus-induced respiratory tract infections are a major health burden in childhood, and available treatments are supportive rather than disease modifying. Rhinoviruses (RVs), the cause of approximately 80% of common colds, are detected in nearly half of all infants with bronchiolitis and the majority of children with an asthma exacerbation. Bronchiolitis in early life is a strong risk factor for the development of asthma. Here, we found that RV infection induced the expression of miRNA 122 (miR-122) in mouse lungs and in human airway epithelial cells. In vivo inhibition specifically in the lung reduced neutrophilic inflammation and CXCL2 expression, boosted innate IFN responses, and ameliorated airway hyperreactivity in the absence and in the presence of allergic lung inflammation. Inhibition of miR-122 in the lung increased the levels of suppressor of cytokine signaling 1 (SOCS1), which is an in vitro-validated target of miR-122. Importantly, gene silencing of SOCS1 in vivo completely reversed the protective effects of miR-122 inhibition on RV-induced lung disease. Higher miR-122 expression in nasopharyngeal aspirates was associated with a longer time on oxygen therapy and a higher rate of treatment failure in 87 infants hospitalized with moderately severe bronchiolitis. These results suggest that miR-122 promotes RV-induced lung disease via suppression of its target SOCS1 in vivo. Higher miR-122 expression was associated with worse clinical outcomes, highlighting the potential use of anti-miR-122 oligonucleotides, successfully trialed for treatment of hepatitis C, as potential therapeutics for RV-induced bronchiolitis and asthma exacerbations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available